IMDX (Insight Molecular Diagnostics Inc.) stock: $4.04, $132.2M market cap, $17.8M cash, $114.4M EV, $172.2M fully diluted market cap. Next expected readout: Dec-32. Data from Fully Diluted's biotech stocks database.
Share price
$4.04
Market cap
$132.2M
Cash
$17.8M
Enterprise value
$114.4M
Balance sheet
Cash
$17.8M
Debt
$0.0M
Net cash
$17.8M
Enterprise value
$114.4M
Basic shares
32.6M shares
Fully diluted shares
42.6M shares
Fully diluted market cap
$172.2M
Cash per share
$0.54
Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.
Price history
Loading IMDX daily closes…
Loading price history…
Pipeline assets
GraftAssureDx
Stage not disclosed · ActiveModality: diagnostic (kitted in vitro diagnostic test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024, to co-develop and commercialize RUO and IVD kitted transplant products; Bio-Rad also an equity investor)
Indications
Kidney transplant (multiple tissue/organ types planned)(Stage not disclosed)
Status note IVD kitted transplant product for clinical use; clinical trial started in 2025 in conjunction with the IVD submission. Kitted tests require FDA marketing authorization (U.S.) and IVDR approval (EU) before clinical use.
GraftAssureIQ
Stage not disclosed · ActiveModality: diagnostic (kitted RUO test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)
Indications
Kidney transplant(Stage not disclosed)
Status note RUO kitted transplant test being developed and commercialized under the Bio-Rad collaboration.
GraftAssureCore
Stage not disclosed · ActiveModality: diagnostic (kitted transplant test)
Partnerships Bio-Rad Laboratories (10-year global strategic partnership, April 2024)
Indications
Kidney transplant(Stage not disclosed)
Status note Named as a current focus of R&D alongside GraftAssureIQ and GraftAssureDx; iMDx depends on the Bio-Rad collaboration for development and commercialization of kitted transplant products.
Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.